These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11053025)

  • 1. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
    Underwood DC; Osborn RR; Bochnowicz S; Webb EF; Rieman DJ; Lee JC; Romanic AM; Adams JL; Hay DW; Griswold DE
    Am J Physiol Lung Cell Mol Physiol; 2000 Nov; 279(5):L895-902. PubMed ID: 11053025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
    Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
    J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.
    Haddad EB; Birrell M; McCluskie K; Ling A; Webber SE; Foster ML; Belvisi MG
    Br J Pharmacol; 2001 Apr; 132(8):1715-24. PubMed ID: 11309243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase.
    Nick JA; Young SK; Arndt PG; Lieber JG; Suratt BT; Poch KR; Avdi NJ; Malcolm KC; Taube C; Henson PM; Worthen GS
    J Immunol; 2002 Nov; 169(9):5260-9. PubMed ID: 12391245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
    Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
    J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
    Barone FC; Irving EA; Ray AM; Lee JC; Kassis S; Kumar S; Badger AM; White RF; McVey MJ; Legos JJ; Erhardt JA; Nelson AH; Ohlstein EH; Hunter AJ; Ward K; Smith BR; Adams JL; Parsons AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):312-21. PubMed ID: 11160612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9.
    Zhao L; Mu B; Zhou R; Cheng Y; Huang C
    Int J Rheum Dis; 2019 Apr; 22(4):686-694. PubMed ID: 30666825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.
    Dong XW; Jia YL; Ge LT; Jiang B; Jiang JX; Shen J; Jin YC; Guan Y; Sun Y; Xie QM
    Toxicology; 2017 Aug; 389():31-41. PubMed ID: 28694203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat.
    Birrell M; Hele D; McCluskie K; Webber S; Foster M; Belvisi MG
    Eur Respir J; 2000 Nov; 16(5):947-50. PubMed ID: 11153597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis.
    Matsuoka H; Arai T; Mori M; Goya S; Kida H; Morishita H; Fujiwara H; Tachibana I; Osaki T; Hayashi S
    Am J Physiol Lung Cell Mol Physiol; 2002 Jul; 283(1):L103-12. PubMed ID: 12060566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of L-gamma-glutamyl-L-cysteinyl-glycine (glutathione/GSH) in the mechanism of redox signaling mediating MAPK(p38)-dependent regulation of pro-inflammatory cytokine production.
    Haddad JJ
    Biochem Pharmacol; 2002 Jan; 63(2):305-20. PubMed ID: 11841806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38 Mitogen-activated protein kinase up-regulates LPS-induced NF-kappaB activation in the development of lung injury and RAW 264.7 macrophages.
    Kim HJ; Lee HS; Chong YH; Kang JL
    Toxicology; 2006 Aug; 225(1):36-47. PubMed ID: 16793190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation.
    Nick JA; Young SK; Brown KK; Avdi NJ; Arndt PG; Suratt BT; Janes MS; Henson PM; Worthen GS
    J Immunol; 2000 Feb; 164(4):2151-9. PubMed ID: 10657669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibitor of p38 mitogen-activated protein kinase inhibits lipopolysaccharide-induced interleukin-8 expression in human pulmonary vascular endothelial cells.
    Hashimoto S; Gon Y; Matsumoto K; Maruoka S; Takeshita I; Hayashi S; Asai Y; Jibiki I; Machino T; Horie T
    J Pharmacol Exp Ther; 2000 May; 293(2):370-5. PubMed ID: 10773004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
    Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
    J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase.
    Guo X; Gerl RE; Schrader JW
    J Biol Chem; 2003 Jun; 278(25):22237-42. PubMed ID: 12637577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.
    Ju H; Behm DJ; Nerurkar S; Eybye ME; Haimbach RE; Olzinski AR; Douglas SA; Willette RN
    J Pharmacol Exp Ther; 2003 Dec; 307(3):932-8. PubMed ID: 14561851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.
    Badger AM; Griswold DE; Kapadia R; Blake S; Swift BA; Hoffman SJ; Stroup GB; Webb E; Rieman DJ; Gowen M; Boehm JC; Adams JL; Lee JC
    Arthritis Rheum; 2000 Jan; 43(1):175-83. PubMed ID: 10643714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of phosphorylated mitogen-activated protein kinases on phosgene inhalation-induced lung injury in rats and its relationship with matrix metalloproteinase].
    Shao YR; Shen J; Li W; Yuan Z; He DK
    Zhonghua Shao Shang Za Zhi; 2013 Jun; 29(3):261-6. PubMed ID: 24059951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation.
    Brando Lima AC; Machado AL; Simon P; Cavalcante MM; Rezende DC; Sperandio da Silva GM; Nascimento PG; Quintas LE; Cunha FQ; Barreiro EJ; Lima LM; Koatz VL
    Pharmacol Rep; 2011; 63(4):1029-39. PubMed ID: 22001991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.